× NICE uses cookies to make the site better.  Learn more
A-Z
Topics
Latest


Lymphoma

history control tooltip

divider handle tooltip

These are the paths in the Blood and bone marrow cancers pathway:

Blood and bone marrow cancers HAI

About

What is covered

This pathway covers blood and bone marrow cancers, including leukaemia, lymphoma and myeloma.
NICE is developing guidance on non-Hodgkin's lymphoma, which is expected to be published in December 2015 and multiple myeloma, which is expected to be published in January 2016.
To find other information about blood and bone marrow cancers, including evidence from NICE Accredited sources, visit NICE Evidence Search.

Updates

Updates to this pathway

16 December 2014 Idelalisib for treating refractory indolent non-Hodgkin's lymphoma (terminated appraisal) NICE technology appraisal 328 added to non-Hodgkin's lymphoma.
22 April 2014 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (NICE technology appraisal guidance 311) added to the multiple myeloma path
14 March 2014 Minor maintenance updates.
25 February 2014 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (NICE technology appraisal guidance 306) added to the lymphoma path
20 February 2014 Amended position of NICE technology appraisal guidance 218 on the leukaemia path
27 January 2014 Minor maintenance updates.

Patient-centred care

Patients and healthcare professionals have rights and responsibilities as set out in the NHS Constitution for England – all NICE guidance is written to reflect these. Treatment and care should take into account individual needs and preferences. People should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If the person is under 16, their family or carers should also be given information and support to help the child or young person to make decisions about their treatment. Healthcare professionals should follow the Department of Health's advice on consent. If someone does not have capacity to make decisions, healthcare professionals should follow the code of practice that accompanies the Mental Capacity Act and the supplementary code of practice on deprivation of liberty safeguards.
For young people moving between paediatric and adult services, care should be planned and managed according to the best practice guidance described in the Department of Health’s Transition: getting it right for young people.
Adult and paediatric healthcare teams should work jointly to provide assessment and services to young people. Diagnosis and management should be reviewed throughout the transition process, and there should be clarity about who is the lead clinician to ensure continuity of care.

Short Text

This pathway covers blood and bone marrow cancers, including leukaemia, lymphoma and myeloma.

What is covered

This pathway covers blood and bone marrow cancers, including leukaemia, lymphoma and myeloma.
NICE is developing guidance on non-Hodgkin's lymphoma, which is expected to be published in December 2015 and multiple myeloma, which is expected to be published in January 2016.
To find other information about blood and bone marrow cancers, including evidence from NICE Accredited sources, visit NICE Evidence Search.

Updates

Updates to this pathway

16 December 2014 Idelalisib for treating refractory indolent non-Hodgkin's lymphoma (terminated appraisal) NICE technology appraisal 328 added to non-Hodgkin's lymphoma.
22 April 2014 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (NICE technology appraisal guidance 311) added to the multiple myeloma path
14 March 2014 Minor maintenance updates.
25 February 2014 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (NICE technology appraisal guidance 306) added to the lymphoma path
20 February 2014 Amended position of NICE technology appraisal guidance 218 on the leukaemia path
27 January 2014 Minor maintenance updates.

Sources

NICE guidance

The NICE guidance that was used to create the pathway.
Bosutinib for previously treated chronic myeloid leukaemia (2013) NICE technology appraisal guidance 299 (2013)
Bendamustine for the treatment of chronic lymphocytic leukaemia (2011) NICE technology appraisal guidance 216
Bortezomib monotherapy for relapsed multiple myeloma (2007) NICE technology appraisal guidance 129
Guidance on the use of imatinib for chronic myeloid leukaemia (2003) NICE technology appraisal guidance 70
Rituximab for aggressive non-Hodgkin's lymphoma (2003) NICE technology appraisal guidance 65

Quality standards

Quality statements

Effective interventions library

Effective interventions library

Successful effective interventions library details

Implementation

Commissioning

These resources include support for commissioners to plan for costs and savings of guidance implementation and meeting quality standards where they apply.
These resources will help to inform discussions with providers about the development of services and may include measurement and action planning tools.

Service improvement and audit

These resources provide help with planning ahead for NICE guidance, understanding where you are now, and conducting improvement initiatives.

Information for the public

NICE produces information for the public that summarises, in plain English, the recommendations that NICE makes to healthcare and other professionals.
NICE has written information for the public explaining its guidance on each of the following topics.

Pathway information

Patient-centred care

Patients and healthcare professionals have rights and responsibilities as set out in the NHS Constitution for England – all NICE guidance is written to reflect these. Treatment and care should take into account individual needs and preferences. People should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals. If the person is under 16, their family or carers should also be given information and support to help the child or young person to make decisions about their treatment. Healthcare professionals should follow the Department of Health's advice on consent. If someone does not have capacity to make decisions, healthcare professionals should follow the code of practice that accompanies the Mental Capacity Act and the supplementary code of practice on deprivation of liberty safeguards.
For young people moving between paediatric and adult services, care should be planned and managed according to the best practice guidance described in the Department of Health’s Transition: getting it right for young people.
Adult and paediatric healthcare teams should work jointly to provide assessment and services to young people. Diagnosis and management should be reviewed throughout the transition process, and there should be clarity about who is the lead clinician to ensure continuity of care.

Supporting information

Glossary

Paths in this pathway

Pathway created: December 2013 Last updated: December 2014

© NICE 2014

Recently viewed